Stromal biology and therapy in pancreatic cancer
The DOI matches its Crossref record; 87 of the 87 references it cites were found in a registry or an index.
Abstract
Pancreatic ductal adenocarcinoma (PDA) is an almost uniformly lethal disease. One explanation for the devastating prognosis is the failure of many chemotherapies, including the current standard of care therapy gemcitabine. Although our knowledge of the molecular events underlying multistep carcinogenesis in PDA has steadily increased, translation into more effective therapeutic approaches has been inefficient over the last several decades. Evidence for this innate resistance to systemic therapies was recently provided in an accurate mouse model of PDA by the demonstration that chemotherapies are poorly delivered to PDA tissues because of a deficient vasculature. This vascular deficiency correlated with the presence of a dense stromal matrix that is a prominent histological hallmark of PDA tumours. Therapeutic targeting of stromal cells decreased the stroma from pancreatic tumours, resulting in increased intratumoral perfusion and therapeutic delivery of gemcitabine. Stromal cells contained within the PDA tumour microenvironment therefore represent an additional constituent to neoplastic cells that should be critically evaluated for optimal therapeutic development in preclinical models and early clinical trials.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Jemal, A., Siegel, R., Ward, E., Hao, Y., Xu, J., Murray, T., & Thun, M. J. (2008) · CA: A Cancer Journal for Clinicians · doi:10.3322/ca.2007.0010 · Cited by 10,188
Spencer, P. M., Cameron, J. L., & Lin, L. (2000) · Cited by 7,202
Genetic Alterations during Colorectal-Tumor Development
Vogelstein, B., Fearon, E. R., Hamilton, S. R., Kern, S. E., Preisinger, A. C., Leppert, M., Smits, A. M. M., & Bos, J. L. (1988) · New England Journal of Medicine · doi:10.1056/nejm198809013190901 · Cited by 6,728
Burris, H. A., Moore, M. J., Andersen, J., Green, M. R., Rothenberg, M. L., Modiano, M. R., Cripps, M. C., Portenoy, R. K., Storniolo, A. M., Tarassoff, P., et al. (1997) · Journal of Clinical Oncology · doi:10.1200/jco.1997.15.6.2403 · Cited by 5,894
Endostatin: an endogenous inhibitor of angiogenesis and tumor growth
O'Reilly, M. S., Boehm, T., Shing, Y., Fukai, N., Vasios, G., Lane, W. S., Flynn, E., Birkhead, J. R., Olsen, B. R., & Folkman, J. (1997) · Cell · doi:10.1016/s0092-8674(00)81848-6 · Cited by 4,486
Moore, M. J., Goldstein, D., Hamm, J., Figer, A., Hecht, J. R., Gallinger, S., Au, H. J., Murawa, P., Walde, D., Wolff, R. A., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.07.9525 · Cited by 3,848
Olive, K. P., Jacobetz, M. A., Davidson, C. J., Gopinathan, A., McIntyre, D., Honess, D., Madhu, B., Goldgraben, M. A., Caldwell, M. E., Allard, D., et al. (2009) · Science · doi:10.1126/science.1171362 · Cited by 3,170
Self-citationHingorani, S. R., Wang, L., Multani, A. S., Combs, C., Deramaudt, T. B., Hruban, R. H., Rustgi, A. K., Chang, S., & Tuveson, D. A. (2005) · Cancer Cell · doi:10.1016/j.ccr.2005.04.023 · Cited by 2,609
Self-citationPreinvasive and invasive ductal pancreatic cancer and its early detection in the mouse
Hingorani, S. R., Petricoin, E. F., Maitra, A., Rajapakse, V., King, C., Jacobetz, M. A., Ross, S., Conrads, T. P., Veenstra, T. D., Hitt, B. A., et al. (2003) · Cancer Cell · doi:10.1016/s1535-6108(03)00309-x · Cited by 2,471
Self-citationStromal gene expression predicts clinical outcome in breast cancer
Finak, G., Bertos, N., Pepin, F., Sadekova, S., Souleimanova, M., Zhao, H., Chen, H., Omeroglu, G., Meterissian, S., Omeroglu, A., et al. (2008) · Nature Medicine · doi:10.1038/nm1764 · Cited by 1,687
Research works printed but not linked: 10
- Rothenberg, 1996, A phase II trial of gemcitabine in patients with 5-FU-refractory pancreas cancer, Ann Oncol, 7, 347, 10.1093/oxfordjournals.annonc.a010600 · doi:10.1093/oxfordjournals.annonc.a010600
- Crist, 1987, Improved hospital morbidity, mortality, and survival after the Whipple procedure, Ann Surg, 206, 358, 10.1097/00000658-198709000-00014 · doi:10.1097/00000658-198709000-00014
- Trede, 1990, Survival after pancreatoduodenectomy. 118 consecutive resections without an operative mortality, Ann Surg, 211, 447, 10.1097/00000658-199004000-00011 · doi:10.1097/00000658-199004000-00011
- 10.1007/s11938-005-0039-3 · DOI
- 10.1111/j.1749-6632.1999.tb09533.x · doi:10.1111/j.1749-6632.1999.tb09533.x
- 10.1002/(SICI)1097-0215(20000101)85:1<14::AID-IJC3>3.0.CO;2-O · doi:10.1002/(sici)1097-0215(20000101)85:1<14::aid-ijc3>3.0.co;2-o
- Buchholz, 2003, SERPINE2 (protease nexin I) promotes extracellular matrix production and local invasion of pancreatic tumors in vivo, Cancer Res, 63, 4945
- 10.1016/j.bbrc.2004.08.229 · doi:10.1016/j.bbrc.2004.08.229
- 10.1159/000107400 · DOI
- 10.1002/cncr.10323 · DOI · Paper page
Cited by
Oncogenic Kras maintains pancreatic tumors through regulation of anabolic glucose metabolism
Ying, H., Kimmelman, A. C., Lyssiotis, C. A., Hua, S., Chu, G. C., Fletcher-Sananikone, E., Locasale, J. W., Son, J., Zhang, H., Coloff, J. L., et al. (2012) · Cell · doi:10.1016/j.cell.2012.01.058 · Cited by 2,043
“It is tempting to speculate that KrasG12D may promote the paracrine secretion of prostromal factors such as Sonic Hedgehog (Neesse et al., 2011); however, further work will be necessary to define this complex relationship.”
Tertiary lymphoid structures in the era of cancer immunotherapy
Sautès-Fridman, C., Petitprez, F., Calderaro, J., & Fridman, W. H. (2019) · Nature reviews. Cancer · doi:10.1038/s41568-019-0144-6 · Cited by 1,884
The hallmarks of cancer metabolism: still emerging
Pavlova, N. N., Zhu, J., & Thompson, C. B. (2022) · Cell Metabolism · doi:10.1016/j.cmet.2022.01.007 · Cited by 1,418
The Pancreas Cancer Microenvironment
Feig, C., Gopinathan, A., Neesse, A., Chan, D. S., Cook, N., & Tuveson, D. A. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-3114 · Cited by 1,316
Self-citationVon Hoff, D. D., Ramanathan, R. K., Borad, M. J., Laheru, D. A., Smith, L. S., Wood, T. E., Korn, R. L., Desai, N., Trieu, V., Iglesias, J. L., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2011.36.5742 · Cited by 1,044
Fibroblast heterogeneity in the cancer wound
Öhlund, D., Elyada, E., & Tuveson, D. (2014) · Journal of Experimental Medicine · doi:10.1084/jem.20140692 · Cited by 926
Self-citationCancer-Associated Fibroblasts: Their Characteristics and Their Roles in Tumor Growth
Shiga, K., Hara, M., Nagasaki, T., Sato, T., Takahashi, H., & Takeyama, H. (2015) · Cancers · doi:10.3390/cancers7040902 · Cited by 774
KRAS: feeding pancreatic cancer proliferation
Bryant, K. L., Mancias, J. D., Kimmelman, A. C., & Der, C. J. (2014) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2013.12.004 · Cited by 675
Laklai, H., Miroshnikova, Y. A., Pickup, M. W., Collisson, E. A., Kim, G. E., Barrett, A. S., Hill, R. C., Lakins, J. N., Schlaepfer, D. D., Mouw, J. K., et al. (2016) · Nature Medicine · doi:10.1038/nm.4082 · Cited by 603
Recent advancements in the use of exosomes as drug delivery systems
Bunggulawa, E. J., Wang, W., Yin, T., Wang, N., Durkan, C., Wang, Y., & Wang, G. (2018) · Journal of Nanobiotechnology · doi:10.1186/s12951-018-0403-9 · Cited by 589
Ene–Obong, A., Clear, A. J., Watt, J., Wang, J., Fatah, R., Riches, J. C., Marshall, J. F., Chin–Aleong, J., Chelala, C., Gribben, J. G., et al. (2013) · Gastroenterology · doi:10.1053/j.gastro.2013.07.025 · Cited by 579
de Sousa Cavalcante, L., & Monteiro, G. (2014) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2014.07.041 · Cited by 576
Stromal biology and therapy in pancreatic cancer: a changing paradigm
Neesse, A., Algül, H., Tuveson, D. A., & Gress, T. M. (2015) · Gut · doi:10.1136/gutjnl-2015-309304 · Cited by 559
Self-citationMace, T. A., Shakya, R., Pitarresi, J. R., Swanson, B., McQuinn, C. W., Loftus, S., Nordquist, E., Cruz-Monserrate, Z., Yu, L., Young, G., et al. (2018) · Gut · doi:10.1136/gutjnl-2016-311585 · Cited by 539
Ting, D. T., Wittner, B. S., Ligorio, M., Vincent Jordan, N., Shah, A. M., Miyamoto, D. T., Aceto, N., Bersani, F., Brannigan, B. W., Xega, K., et al. (2014) · Cell Reports · doi:10.1016/j.celrep.2014.08.029 · Cited by 527
Genetics and biology of pancreatic ductal adenocarcinoma
Ying, H., Dey, P., Yao, W., Kimmelman, A. C., Draetta, G. F., Maitra, A., & DePinho, R. A. (2016) · Genes & Development · doi:10.1101/gad.275776.115 · Cited by 527
Tumor-Promoting Desmoplasia Is Disrupted by Depleting FAP-Expressing Stromal Cells
Lo, A., Wang, L.-C. S., Scholler, J., Monslow, J., Avery, D., Newick, K., O'Brien, S., Evans, R. A., Bajor, D. J., Clendenin, C., et al. (2015) · Cancer Research · doi:10.1158/0008-5472.can-14-3041 · Cited by 498
Pancreatic Cancer Chemoresistance to Gemcitabine
Amrutkar, M., & Gladhaug, I. (2017) · Cancers · doi:10.3390/cancers9110157 · Cited by 448
Dimcevski, G., Kotopoulis, S., Bjånes, T., Hoem, D., Schjøtt, J., Gjertsen, B. T., Biermann, M., Molven, A., Sorbye, H., McCormack, E., et al. (2016) · Journal of Controlled Release · doi:10.1016/j.jconrel.2016.10.007 · Cited by 434
Guillaumond, F., Leca, J., Olivares, O., Lavaut, M.-N., Vidal, N., Berthezène, P., Dusetti, N. J., Loncle, C., Calvo, E., Turrini, O., et al. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1219555110 · Cited by 413
Gemcitabine resistance in pancreatic ductal adenocarcinoma
Binenbaum, Y., Na’ara, S., & Gil, Z. (2015) · Drug Resistance Updates · doi:10.1016/j.drup.2015.10.002 · Cited by 414
Lonardo, E., Hermann, P. C., Mueller, M.-T., Huber, S., Balic, A., Miranda-Lorenzo, I., Zagorac, S., Alcala, S., Rodriguez-Arabaolaza, I., Ramirez, J. C., et al. (2011) · Cell Stem Cell · doi:10.1016/j.stem.2011.10.001 · Cited by 405
Roles for KRAS in Pancreatic Tumor Development and Progression
di Magliano, M. P., & Logsdon, C. D. (2013) · Gastroenterology · doi:10.1053/j.gastro.2013.01.071 · Cited by 400
Overchuk, M., & Zheng, G. (2018) · Biomaterials · doi:10.1016/j.biomaterials.2017.10.024 · Cited by 383
Oncogenic KRAS Regulates Tumor Cell Signaling via Stromal Reciprocation
Tape, C. J., Ling, S., Dimitriadi, M., McMahon, K. M., Worboys, J. D., Leong, H. S., Norrie, I. C., Miller, C. J., Poulogiannis, G., Lauffenburger, D. A., et al. (2016) · Cell · doi:10.1016/j.cell.2016.03.029 · Cited by 369
Stromal biology and therapy in pancreatic cancer: ready for clinical translation?
Neesse, A., Bauer, C. A., Öhlund, D., Lauth, M., Buchholz, M., Michl, P., Tuveson, D. A., & Gress, T. M. (2019) · Gut · doi:10.1136/gutjnl-2018-316451 · Cited by 353
Self-citationGukovsky, I., Li, N., Todoric, J., Gukovskaya, A., & Karin, M. (2013) · Gastroenterology · doi:10.1053/j.gastro.2013.02.007 · Cited by 343
Pancreatic cancer: why is it so hard to treat?
Oberstein, P. E., & Olive, K. P. (2013) · Therapeutic Advances in Gastroenterology · doi:10.1177/1756283x13478680 · Cited by 340
Self-citationMicroenvironmental Determinants of Pancreatic Cancer
Hessmann, E., Buchholz, S. M., Demir, I. E., Singh, S. K., Gress, T. M., Ellenrieder, V., & Neesse, A. (2020) · Physiological Reviews · doi:10.1152/physrev.00042.2019 · Cited by 331
Self-citationRole of Immune Cells and Immune-Based Therapies in Pancreatitis and Pancreatic Ductal Adenocarcinoma
Zheng, L., Xue, J., Jaffee, E. M., & Habtezion, A. (2013) · Gastroenterology · doi:10.1053/j.gastro.2012.12.042 · Cited by 323
Surface-enhanced resonance Raman scattering nanostars for high-precision cancer imaging
Harmsen, S., Huang, R., Wall, M. A., Karabeber, H., Samii, J. M., Spaliviero, M., White, J. R., Monette, S., O’Connor, R., Pitter, K. L., et al. (2015) · Science Translational Medicine · doi:10.1126/scitranslmed.3010633 · Cited by 296
Self-citationCell-free DNA next-generation sequencing in pancreatobiliary carcinomas
Zill, O. A., Greene, C., Sebisanovic, D., Siew, L. M., Leng, J., Vu, M., Hendifar, A. E., Wang, Z., Atreya, C. E., Kelley, R. K., et al. (2015) · Cancer Discovery · doi:10.1158/2159-8290.cd-15-0274 · Cited by 282
Xiao, Z., Todd, L., Huang, L., Noguera-Ortega, E., Lu, Z., Huang, L., Kopp, M., Li, Y., Pattada, N., Zhong, W., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-40850-5 · Cited by 272
Vennin, C., Chin, V. T., Warren, S. C., Lucas, M. C., Herrmann, D., Magenau, A., Melenec, P., Walters, S. N., del Monte-Nieto, G., Conway, J. R. W., et al. (2017) · Science Translational Medicine · doi:10.1126/scitranslmed.aai8504 · Cited by 267
Creation of bladder assembloids mimicking tissue regeneration and cancer
Kim, E., Choi, S., Kang, B., Kong, J., Kim, Y., Yoon, W. H., Lee, H.-R., Kim, S., Kim, H.-M., Lee, H., et al. (2020) · Nature · doi:10.1038/s41586-020-3034-x · Cited by 260
Modeling tumor phenotypes in vitro with three-dimensional bioprinting
Langer, E. M., Allen-Petersen, B. L., King, S. M., Kendsersky, N. D., Turnidge, M. A., Kuziel, G. M., Riggers, R., Samatham, R., Amery, T. S., Jacques, S. L., et al. (2019) · Cell Reports · doi:10.1016/j.celrep.2018.12.090 · Cited by 256
A pilot study to explore circulating tumour cells in pancreatic cancer as a novel biomarker
Khoja, L., Backen, A., Sloane, R., Menasce, L., Ryder, D., Krebs, M., Board, R., Clack, G., Hughes, A., Blackhall, F., et al. (2012) · British Journal of Cancer · doi:10.1038/bjc.2011.545 · Cited by 255
Vazquez, A., Kamphorst, J. J., Markert, E. K., Schug, Z. T., Tardito, S., & Gottlieb, E. (2016) · Journal of Cell Science · doi:10.1242/jcs.181016 · Cited by 225
Targeting tumor-intrinsic hexosamine biosynthesis sensitizes pancreatic cancer to anti-PD1 therapy
Sharma, N. S., Gupta, V. K., Garrido, V. T., Hadad, R., Durden, B. C., Kesh, K., Giri, B., Ferrantella, A., Dudeja, V., Saluja, A., et al. (2019) · Journal of Clinical Investigation · doi:10.1172/jci127515 · Cited by 203
“High rates of tumor relapse, therapeutic resistance, and metastatic spread of the tumor contribute to these dismal statistics (3, 4).”
BackgroundZhu, Z., Achreja, A., Meurs, N., Animasahun, O., Owen, S., Mittal, A., Parikh, P., Lo, T.-W., Franco-Barraza, J., Shi, J., et al. (2020) · Nature Metabolism · doi:10.1038/s42255-020-0226-5 · Cited by 204
Dynamic Mast Cell–Stromal Cell Interactions Promote Growth of Pancreatic Cancer
Ma, Y., Hwang, R. F., Logsdon, C. D., & Ullrich, S. E. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-4479 · Cited by 186
Transport properties of pancreatic cancer describe gemcitabine delivery and response
Koay, E. J., Truty, M. J., Cristini, V., Thomas, R. M., Chen, R., Chatterjee, D., Kang, Y., Bhosale, P. R., Tamm, E. P., Crane, C. H., et al. (2014) · Journal of Clinical Investigation · doi:10.1172/jci73455 · Cited by 184
Truong, L.-H., & Pauklin, S. (2021) · Cancers · doi:10.3390/cancers13195028 · Cited by 102
Inhibition of mutagenic translesion synthesis: A possible strategy for improving chemotherapy?
Yamanaka, K., Chatterjee, N., Hemann, M. T., & Walker, G. C. (2017) · PLOS Genetics · doi:10.1371/journal.pgen.1006842 · Cited by 87
“Many tumors, including most pancreatic adenocarcinomas, nonsmall cell lung cancers, and aggressive brain tumors, as well as most metastatic malignancies, fail to significantly regress following chemotherapy [2].”
BackgroundInfluentialToward the broad adoption of 3D tumor models in the cancer drug pipeline
Cox, M. C., Reese, L. M., Bickford, L. R., & Verbridge, S. S. (2015) · ACS Biomaterials Science & Engineering · doi:10.1021/acsbiomaterials.5b00172 · Cited by 80
Garcia, P. L., Miller, A. L., & Yoon, K. J. (2020) · Cancers · doi:10.3390/cancers12051327 · Cited by 77
Drifka, C. R., Eliceiri, K. W., Weber, S. M., & Kao, W. J. (2013) · Lab on a Chip · doi:10.1039/c3lc50487e · Cited by 64
Selective impact of CDK4/6 suppression on patient-derived models of pancreatic cancer
Witkiewicz, A. K., Borja, N. A., Franco, J., Brody, J. R., Yeo, C. J., Mansour, J., Choti, M. A., McCue, P., & Knudsen, E. S. (2015) · Oncotarget · doi:10.18632/oncotarget.3819 · Cited by 56
“Additionally, the tumor is dominated by desmoplastic stroma that has recently emerged as a tumor suppressive feature of the disease though it also inhibits drug uptake [30, 39-41].”
BackgroundLuo, J., Cao, J., Ma, G., Wang, X., Sun, Y., Zhang, C., Shi, Z., Zeng, Y., Zhang, T., & Huang, P. (2022) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.2c08951 · Cited by 47
Harnessing Extracellular Matrix Biology for Tumor Drug Delivery
Subrahmanyam, N., & Ghandehari, H. (2021) · Journal of Personalized Medicine · doi:10.3390/jpm11020088 · Cited by 42
A biomimetic tumor model of heterogeneous invasion in pancreatic ductal adenocarcinoma
Bradney, M. J., Venis, S. M., Yang, Y., Konieczny, S. F., & Han, B. (2020) · Small · doi:10.1002/smll.201905500 · Cited by 38
Gregucci, F., Fiorentino, A., Mazzola, R., Ricchetti, F., Bonaparte, I., Surgo, A., Figlia, V., Carbonara, R., Caliandro, M., Ciliberti, M. P., et al. (2022) · La radiologia medica · doi:10.1007/s11547-021-01422-z · Cited by 38
ZEEBERG, K., CARDONE, R. A., GRECO, M. R., SACCOMANO, M., NØHR-NIELSEN, A., ALVES, F., PEDERSEN, S. F., & RESHKIN, S. J. (2016) · International Journal of Oncology · doi:10.3892/ijo.2016.3513 · Cited by 33
“Indeed, among all cancer types PDAC, due to the strong interplay between tumor cells and stromal components, exhibits the most dense desmoplastic stroma which can account for up to 90% of the total tumor volume (4).”
Background
Metadata
- Authors
- Neesse, A., Michl, P., Frese, K. K., Feig, C., Cook, N., Jacobetz, M. A., Lolkema, M. P., Buchholz, M., Olive, K. P., Gress, T. M., & Tuveson, D. A.
- Venue
- Gut
- Publisher
- BMJ
- Published
- 2010-10-21
- Volume
- 60
- Issue
- 6
- Pages
- 861-868
- ISSN
- 0017-5749 (ISSN-L)
- 1468-3288
- OpenAlex
- W2131070390
- Cited by
- 757
- References
- 87
- FWCI
- 14.67
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.